How is retatrutide dosed and mixed?

Draw to

unitsmL

0.3 mL · 30 units syringe0.5 mL · 50 units syringe1 mL · 100 units syringe3 mL · 3cc syringe0.5 mL · 20 units, U-40 syringe1 mL · 40 units, U-40 syringe

051015202530 01020304050 0102030405060708090100 00.511.522.53 05101520 010203040

    mL
    Most often logged by Milligram users
    Syringe scale
    Syringe

    Concentration is the powder in the vial divided by the water. The draw is the dose divided by the concentration, in mL, times 100 on a U-100 syringe or 40 on a U-40. Every figure comes from what you enter.

    Save to Milligram
    How often

    Open in Milligram shows once the calculator has a result.

    Open in Milligram is off while the dose is more than the whole vial. Check the dose and its unit.

    Open in Milligram is off while the draw is under one unit. Check the dose and its unit.

    Open in Milligram adds Retatrutide and this dose to a plan in the app, with the schedule you pick here. The vial and water are not saved.

    No regulator label gives a retatrutide dose; in the phase 3 TRIUMPH-1 trial (Jastreboff 2026), 2339 adults with obesity without diabetes were randomly assigned to once-weekly subcutaneous retatrutide (4 mg, 9 mg or 12 mg) or placebo for 80 weeks, and a 2026 review, citing sponsor disclosures, says the reported phase 3 regimens began at 2 mg weekly and rose at 4-week intervals.12

    The guide's example

    2 mg of Retatrutide from a 10 mg vial mixed with 1 mL is 20 units on a U-100 syringe.

    Every vial at a glance. Pick a cell to draw it on the syringe.

    Concentration is the vial's amount over its water; units are the dose over the concentration, times 100, on a U-100 syringe.
    Vial1 mL of water2 mL of water3 mL of water
    10 mg39% set up1410 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 3 mg is 30 units, 4 mg is 40 units5 mg/mL: 1 mg is 20 units, 2 mg is 40 units, 3 mg is 60 units, 4 mg is 80 units3.333 mg/mL: 1 mg is 30 units, 2 mg is 60 units, 3 mg is 90 units, 4 mg is over 1 mL
    20 mg27% set up1420 mg/mL: 1 mg is 5 units, 2 mg is 10 units, 3 mg is 15 units, 4 mg is 20 units10 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 3 mg is 30 units, 4 mg is 40 units6.667 mg/mL: 1 mg is 15 units, 2 mg is 30 units, 3 mg is 45 units, 4 mg is 60 units
    30 mg16% set up1430 mg/mL: 1 mg is 3.3 units, 2 mg is 6.7 units, 3 mg is 10 units, 4 mg is 13.3 units15 mg/mL: 1 mg is 6.7 units, 2 mg is 13.3 units, 3 mg is 20 units, 4 mg is 26.7 units10 mg/mL: 1 mg is 10 units, 2 mg is 20 units, 3 mg is 30 units, 4 mg is 40 units

    Most often logged by Milligram users: 2 mg, 22% logged.14

    Jump to a vial 10 mg 20 mg 30 mg

    Retatrutide vial chart: water and syringe units

    The Humulin R insulin label gives U-100 as 100 units/mL, which sets the scale of a U-100 syringe.3 At 10 mg with 3 mL, a 4 mg dose is 1.2 mL, more than a 1 mL U-100 syringe holds.3 Of the people who logged retatrutide, 39% set up a 10 mg vial, 27% a 20 mg vial and 16% a 30 mg vial.14

    2 mg of Retatrutide from a 10 mg vial mixed with 1 mL is 20 units on a U-100 syringe.

    19% set up 10 mg + 1 mL14

    The calculator is at the top of the page

    The only mixing instruction found is a seller's leaflet listed on DailyMed, which is not an approved label: a kit of 10 mg of powder with 1 mL of sterile water for injection, giving 10 mg per mL.4

    What the trials and labels say about dose

    The FDA says retatrutide is not part of any FDA-approved drug.5

    TrialDose and schedulePeopleLength
    Jastreboff 2023, phase 2 obesity trial6Once weekly, under the skin, against placebo: 1 mg; 4 mg (initial dose 2 mg or 4 mg); 8 mg (initial dose 2 mg or 4 mg); or 12 mg (initial dose 2 mg)338 adults with a BMI of 30 or higher, or 27 to under 30 with a weight-related condition48 weeks
    Rosenstock 2023, phase 2 type 2 diabetes trial7Once weekly, against placebo or 1·5 mg dulaglutide: 0·5 mg; 4 mg (starting dose 2 mg); 4 mg (no escalation); 8 mg (starting dose 2 mg); 8 mg (starting dose 4 mg); or 12 mg (starting dose 2 mg)281 participants with type 2 diabetes24 weeks (primary endpoint); 36 weeks (secondary endpoints)
    Jastreboff 2026, TRIUMPH-11Once weekly, under the skin, against placebo: 4 mg, 9 mg, or 12 mg2339 adults with obesity without diabetes80 weeks
    Bellido 2026, TRIUMPH-28Once weekly, under the skin (self-administered), against placebo: 4 mg, 9 mg, or 12 mg1152 adults with obesity and type 2 diabetesWeek 80 (primary endpoint)
    Bajaj 2026, TRANSCEND-T2D-19Once weekly, under the skin, against placebo: 4 mg, 9 mg, or 12 mg537 adults with type 2 diabetes40 weeks
    Schnitzer 2026, TRIUMPH-4 and TRIUMPH-1-OA10Once weekly, under the skin, against placebo: 9 or 12 mg (TRIUMPH-4); 4, 9, or 12 mg (TRIUMPH-1-OA)445 and 574 adults without diabetes with painful knee osteoarthritis and a BMI of at least 2768 weeks; 80 weeks
    Urva 2022, phase 1b type 2 diabetes trial11Once weekly, under the skin, against placebo or dulaglutide: 0·5 mg, 1·5 mg, 3 mg, 3/6 mg, or 3/6/9/12 mg72 adults with type 2 diabetes12 weeks

    In the phase 2 obesity trial (Jastreboff 2023, 338 adults, 48 weeks), the most common adverse events with retatrutide were gastrointestinal; these were dose-related, mostly mild to moderate in severity, and partially mitigated with a lower starting dose (2 mg vs. 4 mg).6 A 2026 review, citing sponsor disclosures, says the reported phase 3 regimens began at 2 mg weekly and rose at 4-week intervals: 2 to 4 mg; 2, 4, 6 then 9 mg; or 2, 4, 6, 9 then 12 mg; the TRIUMPH and TRANSCEND-T2D-1 trial summaries give group doses only.2

    Of the people who logged a retatrutide dose step, 36% set a 28-day interval and 30% a 14-day interval.14

    How long mixed retatrutide keeps

    Seller leaflets on DailyMed give no storage temperature or time for the retatrutide powder or pen.4 A bacteriostatic water label says not to store reconstituted drug solutions unless the drug's manufacturer directs it.12 A 2026 review lists stability under storage, transport and in-use conditions as a development consideration, not a measured retatrutide characteristic.2 FDA recommends using a multiple-dose vial of a sterile medication within 28 days after first use; a general rule, not a retatrutide figure.5

    Frequently asked questions

    Where is retatrutide injected?

    In the phase 2 obesity trial (338 adults), TRIUMPH-1 (2339 participants) and TRANSCEND-T2D-1 (537 adults), retatrutide was given by once-weekly subcutaneous injection; no trial summary read names an injection site.619 Of the people who logged retatrutide, 97% logged under the skin and 3% muscle.14

    Do human data exist for retatrutide microdosing?

    A query of PubMed for retatrutide with the term microdos* returned no items.13 No trial or label found defines or tests a retatrutide microdose; the lowest weekly doses in the trials found were 0·5 mg (Rosenstock 2023, 281 participants; Urva 2022, 72 adults) and 1 mg (Jastreboff 2023, 338 adults).7116 A review reports a first-in-human study of single doses from 0.1 to 6 mg under the skin in 45 healthy participants.2

    What is known about retatrutide with other peptides or testosterone?

    A review says retatrutide-specific interaction evidence is limited and that the absence of clinically relevant interactions requires product-specific evaluation.2 Of the people who logged retatrutide, 17% also logged GHK-Cu, 17% MOTS-c, 15% tesamorelin, 14% testosterone enanthate and 10% testosterone cypionate.14

    How the logged figures are counted

    Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

    References

    1. NEJM (PubMed abstract). Retatrutide TRIUMPH-1 phase 3. 2026. eutils.ncbi.nlm.nih.gov
    2. Pharmaceutics (MDPI), full text. Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist. 2026. pmc.ncbi.nlm.nih.gov
    3. Eli Lilly (DailyMed). Humulin R (insulin human) injection U-100 label. 2026. dailymed.nlm.nih.gov
    4. Guangzhou Yixin Cross-border E-commerce Co., Ltd. (listed on DailyMed, unapproved). Retatrutide lyophilized powder kit, seller leaflet. 2025. dailymed.nlm.nih.gov
    5. US Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2026. fda.gov
    6. NEJM (PubMed abstract). Retatrutide phase 2 obesity trial (NCT04881760). 2023. eutils.ncbi.nlm.nih.gov
    7. Lancet (PubMed abstract). Retatrutide phase 2 type 2 diabetes trial. 2023. eutils.ncbi.nlm.nih.gov
    8. Lancet (PubMed abstract). Retatrutide TRIUMPH-2 phase 3. 2026. eutils.ncbi.nlm.nih.gov
    9. PubMed abstract. Retatrutide TRANSCEND-T2D-1 phase 3. 2026. eutils.ncbi.nlm.nih.gov
    10. NEJM (PubMed abstract). Retatrutide TRIUMPH-4 and TRIUMPH-1-OA. 2026. eutils.ncbi.nlm.nih.gov
    11. Lancet (PubMed abstract). LY3437943 phase 1b in type 2 diabetes. 2022. eutils.ncbi.nlm.nih.gov
    12. Henry Schein (DailyMed). Bacteriostatic Water for Injection, USP 30 mL label. 2026. dailymed.nlm.nih.gov
    13. PubMed (NCBI). PubMed search: retatrutide AND microdos*. 2026. eutils.ncbi.nlm.nih.gov
    14. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted